The World Health Organization defines pharmacovigilance, often known as drug safety, as "the science and activities concerned with the detection, assessment, understanding, and prevention of adverse effects or other drug-related problems." The ultimate purpose of pharmacovigilance is to ensure that medicines are used safely, with the dangers associated with the medical product being minimized and the benefits being maximized. It is critical in ensuring that doctors and patients have adequate information to make an informed decision when selecting a medicine for treatment. Mechanisms for evaluating and monitoring the safety of therapeutics in clinical use are critical for preventing or reducing harm to patients and consequently improving public health. In the next ten years, pharmacovigilance programs will briefly outline the probable ramifications of such tendencies on the evolution of science. In this global pitch, pharmacovigilance is confronting numerous problems in developing improved health care systems.
Title : Liver biopsy handling of Metabolic-Associated Fatty Liver Disease (MAFLD): The children's hospital of eastern Ontario grossing protocol
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Haptoglobin-Related Protein Without Signal Peptide as biomarker of renal salt wasting (HPRWSP) in hyponatremia, hyponatremia-related diseases and as new syndrome in alzheimer’s disease
John K Maesaka, NYU Langone Hospital Long Island, United States
Title : Revolutionizing healthcare and pharma: Artificial intelligence-powered scientific communications and medical writing
Alessandro Gallo, Springer Healthcare, Italy
Title : Enabling knowledge-driven integration and interoperability in intelligent and ethical transformed health ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model to be set up via biodesign-driven biotech and upgraded biomarketing to secure the human healthcare and biosafety
Sergey Suchkov, The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Title : Integration of nanotechnology into complex treatment of multiple sclerosis
Andrey Belousov, Kharkiv National Medical University, Ukraine
Title : Preparation and characterization of fibers made from PCL/PVP-ChAgG, along with exploring their potential as wound dressings
Luis Jesus Villarreal Gomez, Autonomous University of Baja California, Mexico
Title : Photoremoval of ketoprofen, naproxen and phenazopyridine from pharmaceutical residues in a hospital wastewater treatment plant via Fe3O4-MnO2@rGO nanocomposite
Delia Teresa Sponza, Dokuz Eylul University, Turkey
Title : Combating aluminium chloride-induced alzheimer's in rats: Neuroprotective effects of Nelumbo nucifera and Bergenia ligulate
Nilay Solanki, Ramanbhai Patel College of Pharmacy, India
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets. Discovery of agonists and antagonists of OR51E1, an understudied G Protein-Coupled Receptor
Vladlen Slepak, University of Miami, United States